CY1118707T1 - Her2 dna εμβολιο ως συμπληρωματικη αγωγη για καρκινους σε ζωα συντροφιας - Google Patents
Her2 dna εμβολιο ως συμπληρωματικη αγωγη για καρκινους σε ζωα συντροφιαςInfo
- Publication number
- CY1118707T1 CY1118707T1 CY20171100185T CY171100185T CY1118707T1 CY 1118707 T1 CY1118707 T1 CY 1118707T1 CY 20171100185 T CY20171100185 T CY 20171100185T CY 171100185 T CY171100185 T CY 171100185T CY 1118707 T1 CY1118707 T1 CY 1118707T1
- Authority
- CY
- Cyprus
- Prior art keywords
- animals
- cancer
- her2
- dna vaccine
- vaccines
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title 1
- 241001465754 Metazoa Species 0.000 title 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 101150029707 ERBB2 gene Proteins 0.000 abstract 2
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 241000282326 Felis catus Species 0.000 abstract 1
- 108090000244 Rat Proteins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000013600 plasmid vector Substances 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η αίτηση γνωστοποιεί θεραπευτικά εμβόλια τα οποία βασίζονται στον "pING" DNA πλασμιδικό φορέα ο οποίος εκφράζει το γονίδιο το οποίο κωδικοποιεί την Her2 πρωτεΐνη αρουραίου. Εμβόλια σύμφωνα με την παρούσα γνωστοποίηση χρησιμοποιούνται ως μια συμπληρωματική αγωγή για χειρουργική επέμβαση, ακτινοβολία και/ή χημειοθεραπεία για σκύλους και γάτες με καρκίνους οι οποίοι υπερεκφράζουν το Her2 αντιγόνο, και παρατείνουν το μετεγχειρητικό ελεύθερης νόσου διάστημα και/ή τον χρόνο επιβίωσης. Επίσης περιλαμβάνονται θεραπευτικώς αποτελεσματικές μέθοδοι ανοσοποίησης οι οποίες χρησιμοποιούν τα εν λόγω εμβόλια.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39450510P | 2010-10-19 | 2010-10-19 | |
| PCT/US2011/056122 WO2012054294A1 (en) | 2010-10-19 | 2011-10-13 | Her2 dna vaccine as adjunct treatment for cancers in companion animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118707T1 true CY1118707T1 (el) | 2017-07-12 |
Family
ID=44906393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100185T CY1118707T1 (el) | 2010-10-19 | 2017-02-08 | Her2 dna εμβολιο ως συμπληρωματικη αγωγη για καρκινους σε ζωα συντροφιας |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9040053B2 (el) |
| EP (1) | EP2629791B1 (el) |
| JP (2) | JP6113659B2 (el) |
| AU (1) | AU2011318369B2 (el) |
| CA (1) | CA2815125C (el) |
| CY (1) | CY1118707T1 (el) |
| DK (1) | DK2629791T3 (el) |
| ES (1) | ES2614880T3 (el) |
| HR (1) | HRP20170253T1 (el) |
| HU (1) | HUE030860T2 (el) |
| LT (1) | LT2629791T (el) |
| ME (1) | ME02604B (el) |
| MX (1) | MX343848B (el) |
| NZ (1) | NZ609198A (el) |
| PL (1) | PL2629791T3 (el) |
| PT (1) | PT2629791T (el) |
| RS (1) | RS55692B1 (el) |
| SI (1) | SI2629791T1 (el) |
| SM (1) | SMT201700061B (el) |
| WO (1) | WO2012054294A1 (el) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ609198A (en) * | 2010-10-19 | 2014-06-27 | Merial Inc | Her2 dna vaccine as adjunct treatment for cancers in companion animals |
| US10434152B2 (en) * | 2014-02-20 | 2019-10-08 | Wayne State University | HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas |
| US10010499B2 (en) | 2014-11-03 | 2018-07-03 | Merial Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820180B2 (en) | 2004-09-24 | 2010-10-26 | The Trustees Of The University Of Pennsylvania | Listeria-based and LLO-based vaccines |
| JP3993898B2 (ja) * | 1996-12-10 | 2007-10-17 | スローン−ケッタリング インスティチュート フォー キャンサー リサーチ | 改変された分化抗原によって刺激される分化抗原に対する免疫応答を刺激するための方法及び組成物 |
| US6328969B1 (en) | 1996-12-10 | 2001-12-11 | Sloan-Kettering Institute For Cancer Research | Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen |
| US7556805B2 (en) * | 1996-12-10 | 2009-07-07 | Sloan-Kettering Inststute for Cancer Research and The Animal Medical Center | Compositions for treatment of melanoma and method of using same |
| CA2545164C (en) * | 2003-11-12 | 2016-11-29 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Recombinant vectors expressing mucin and carcinoembryoinic antigen |
| EP1687432A4 (en) * | 2003-11-13 | 2008-08-27 | Sloan Kettering Inst Cancer | COMPOSITIONS AND METHODS FOR SYNERGISTIC INDUCTION OF ANTITUMOR IMMUNITY |
| US9084747B2 (en) * | 2009-11-11 | 2015-07-21 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors |
| NZ609198A (en) * | 2010-10-19 | 2014-06-27 | Merial Inc | Her2 dna vaccine as adjunct treatment for cancers in companion animals |
-
2011
- 2011-10-13 NZ NZ609198A patent/NZ609198A/en unknown
- 2011-10-13 AU AU2011318369A patent/AU2011318369B2/en active Active
- 2011-10-13 MX MX2013004222A patent/MX343848B/es active IP Right Grant
- 2011-10-13 JP JP2013534954A patent/JP6113659B2/ja active Active
- 2011-10-13 HU HUE11770986A patent/HUE030860T2/en unknown
- 2011-10-13 PT PT117709865T patent/PT2629791T/pt unknown
- 2011-10-13 LT LTEP11770986.5T patent/LT2629791T/lt unknown
- 2011-10-13 RS RS20170129A patent/RS55692B1/sr unknown
- 2011-10-13 SI SI201131121A patent/SI2629791T1/sl unknown
- 2011-10-13 DK DK11770986.5T patent/DK2629791T3/en active
- 2011-10-13 CA CA2815125A patent/CA2815125C/en active Active
- 2011-10-13 EP EP11770986.5A patent/EP2629791B1/en active Active
- 2011-10-13 ME MEP-2017-31A patent/ME02604B/me unknown
- 2011-10-13 US US13/272,651 patent/US9040053B2/en active Active
- 2011-10-13 ES ES11770986.5T patent/ES2614880T3/es active Active
- 2011-10-13 PL PL11770986T patent/PL2629791T3/pl unknown
- 2011-10-13 WO PCT/US2011/056122 patent/WO2012054294A1/en active Application Filing
-
2015
- 2015-04-29 US US14/699,296 patent/US9901628B2/en active Active
-
2016
- 2016-09-01 JP JP2016170583A patent/JP6297641B2/ja active Active
-
2017
- 2017-01-26 SM SM201700061T patent/SMT201700061B/it unknown
- 2017-02-08 CY CY20171100185T patent/CY1118707T1/el unknown
- 2017-02-16 HR HRP20170253TT patent/HRP20170253T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120093841A1 (en) | 2012-04-19 |
| US9901628B2 (en) | 2018-02-27 |
| HRP20170253T1 (hr) | 2017-04-07 |
| SMT201700061B (it) | 2017-03-08 |
| WO2012054294A1 (en) | 2012-04-26 |
| EP2629791B1 (en) | 2016-12-07 |
| ES2614880T3 (es) | 2017-06-02 |
| AU2011318369A1 (en) | 2013-05-02 |
| NZ609198A (en) | 2014-06-27 |
| DK2629791T3 (en) | 2017-01-23 |
| JP6113659B2 (ja) | 2017-04-12 |
| HUE030860T2 (en) | 2017-06-28 |
| MX343848B (es) | 2016-11-24 |
| MX2013004222A (es) | 2013-06-05 |
| CA2815125C (en) | 2024-03-05 |
| US9040053B2 (en) | 2015-05-26 |
| RS55692B1 (sr) | 2017-07-31 |
| JP6297641B2 (ja) | 2018-03-20 |
| SI2629791T1 (sl) | 2017-05-31 |
| EP2629791A1 (en) | 2013-08-28 |
| JP2013545447A (ja) | 2013-12-26 |
| ME02604B (me) | 2017-06-20 |
| AU2011318369B2 (en) | 2014-10-02 |
| PT2629791T (pt) | 2017-03-03 |
| CA2815125A1 (en) | 2012-04-26 |
| US20150374808A1 (en) | 2015-12-31 |
| LT2629791T (lt) | 2017-02-27 |
| JP2016208988A (ja) | 2016-12-15 |
| PL2629791T3 (pl) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125429T1 (el) | Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης | |
| CY1124558T1 (el) | Προβλεψη επιτοπων τ κυτταρων χρησιμων για εμβολιασμο | |
| CY1123978T1 (el) | Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf | |
| CY1121223T1 (el) | Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας | |
| CY1119219T1 (el) | Anti-ceacam5 αντισωματα και χρησεις αυτων | |
| CY1123258T1 (el) | Μεθοδος θεραπειας για τον καρκινο | |
| CY1123902T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι tου καρκινου του οισοφαγου και αλλων καρκινων | |
| CY1123854T1 (el) | Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του καρκινου του προστατη και αλλων καρκινων | |
| EA201700181A1 (ru) | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования | |
| CY1125068T1 (el) | Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων | |
| CY1124279T1 (el) | Ανοσοθεραπεια βασισμενη στη 2,3 διοξυγοναση της ινδολεαμινης | |
| CY1121691T1 (el) | Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου | |
| CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
| CY1124224T1 (el) | Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια κατα του καρκινου του μαστου και αλλων καρκινων | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| CY1119893T1 (el) | Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων | |
| CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
| CY1121535T1 (el) | Πρωτεϊνικα κατασκευασματα uspa2 και χρησεις αυτων | |
| EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| CY1122453T1 (el) | Νεα ανοσοθεραπεια εναντι διαφορων ογκων, οπως καρκινος του πνευμονα, οπου συμπεριλαμβανεται nsclc | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
| CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
| EA201490974A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С ДЕЛЕЦИОННЫМ МУТАНТОМ vIII ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА | |
| CY1123743T1 (el) | Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου |